Status:
COMPLETED
A Study of Avastin (Bevacizumab) Plus Herceptin (Trastuzumab) in Patients With Primary Inflammatory HER2-Positive Breast Cancer.
Lead Sponsor:
Hoffmann-La Roche
Conditions:
Breast Cancer
Eligibility:
FEMALE
18+ years
Phase:
PHASE2
Brief Summary
This single arm study will assess the efficacy and safety of preoperative treatment with Avastin combined with Herceptin-based chemotherapy in patients with primary inflammatory HER2-positive breast c...
Eligibility Criteria
Inclusion
- adult females, \>=18 years of age;
- inflammatory breast cancer;
- HER2-positive tumors;
- performance status 0-2.
Exclusion
- metastases;
- previous treatment with chemotherapy, radiation therapy or hormone therapy for a breast tumor;
- clinically significant cardiovascular disease, or history of thrombotic disorders.
Key Trial Info
Start Date :
October 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 1 2014
Estimated Enrollment :
52 Patients enrolled
Trial Details
Trial ID
NCT00717405
Start Date
October 1 2008
End Date
October 1 2014
Last Update
August 2 2016
Active Locations (28)
Enter a location and click search to find clinical trials sorted by distance.
1
Besançon, France, 25030
2
Bordeaux, France, 33000
3
Brest, France, 29609
4
Caen, France, 14076